Find investors who align with your industry, stage, and vision. Unlock Paul Manning’s full investment profile, including location, investment focus, portfolio companies, and preferences. Sign up today and start building investor relationships that fuel your startup’s growth.
Get connected with all investors todayPaul Manning is a Venture Capital, Private Equity Firm based in Charlottesville, Virginia, United States with a diverse investment portfolio that includes companies such as LEXEO Therapeutics, Nanoview Biosciences, PatientsLikeMe, Candel, Verona Pharma, Landos Biopharma, ArcherDX, SalioGen Therapeutics, Atsena TherapeuticsTaysha Gene Therapies, . Over time, Paul Manning has demonstrated experience in supporting a range of businesses across various sectors.
While it is not publicly confirmed whether Paul Manning is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.
Startups and entrepreneurs operating in sectors related to Patient Care, Health Care, Genetics, Wellness, Consumer Goods, Rare Diseases, Life Science, Portfolio Management, Information Services, Information Technology (IT), Venture Fundraising, Business Development, Finance, Software, Manufacturing, Biotechnology, Drug Development, Genomics, Clinical Trials, Gene Therapy, Consulting, Marketing, Health Diagnostics, Regulatory Compliance, Medical, Sales, B2B, Therapeutics, Cellular Therapy, Media and Entertainment, Pharmaceuticals, Acquisitions may find it worthwhile to explore potential connections with Paul Manning, as their portfolio suggests a familiarity and interest in this area.
Understanding Paul Manning’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.
Angel Match is the easiest way to research investors for your startup so you can spend less time Googling and more time raising.
Find the perfect investors today